High-density lipoprotein inhibits the uptake of modified low- density lipoprotein and the expression of CD36 and FcγRI

9Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Aim: Modified low-density lipoprotein (mLDL), mainly upon oxidative and enzymatic modification, is the major atherogenic lipoprotein. Conversely, high-density lipoprotein (HDL) is considered antiatherogenic because of its ability to remove cholesterol. The aim of this work was to analyze both the influence of HDL on the uptake of mLDL and the expression of CD36 and Fcγ I receptors on monocytic cell lines during cell differentiation. &Methods: Uptake of fluorescein isothiocyanate (FITC)-conjugated LDL and FITC-conjugated mLDL, i.e., copper-oxidized LDL (oxLDL) or trypsin enzyme modified LDL (enzLDL), was analyzed, as well as the expression of CD36 and FcγRI in THP-1 and U937 cells, using flow cytometry. &Results: HDL inhibited the uptake of mLDL, which varied in degree depending on the cell line or type of mLDL. Further, HDL rapidly decreased CD36 and FcγRI involved in the uptake of mLDL. &Conclusions: We demonstrate that modified LDL promotes specific LDL receptor-independent uptake by monocytic cell lines, and that the uptake of LDL and enzLDL is less than that of oxLDL. In this process, HDL diminishes the uptake of LDL or mLDL, which may involve the down-regulation of receptors (CD36 and Fcγ I). This regulatory process represents another way by which HDL can be anti-atherogenic and it depends on the type of modification of LDL and the stage of differentiation of monocytes to macrophages.

References Powered by Scopus

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

219979Citations
N/AReaders
Get full text

Atherosclerosis - An inflammatory disease

20055Citations
N/AReaders
Get full text

The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

6759Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cd36 in chronic kidney disease: Novel insights and therapeutic opportunities

178Citations
N/AReaders
Get full text

High-Density Lipoproteins: Structure, Metabolism, Function, and Therapeutics

66Citations
N/AReaders
Get full text

Uptake of oxLDL and IL-10 Production by Macrophages Requires PAFR and CD36 Recruitment into the Same Lipid Rafts

45Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Carvalho, M. D. T., Vendrame, C. M. V., Ketelhuth, D. F. J., Yamashiro-Kanashiro, E. H., Goto, H., & Gidlund, M. (2010). High-density lipoprotein inhibits the uptake of modified low- density lipoprotein and the expression of CD36 and FcγRI. Journal of Atherosclerosis and Thrombosis, 17(8), 844–857. https://doi.org/10.5551/jat.3905

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Researcher 2

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

57%

Nursing and Health Professions 1

14%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Environmental Science 1

14%

Save time finding and organizing research with Mendeley

Sign up for free